药物预防对根治性前列腺切除术后静脉血栓栓塞的影响:PREVENTER随机临床试验
这项前瞻性4期单中心随机试验纳入501例接受开放或机器人辅助腹腔镜根治性前列腺切除术的前列腺癌患者,比较围手术期皮下肝素药物预防加常规护理与单纯常规护理。结果显示药物预防未显著降低30天症状性静脉血栓栓塞发生率(2.0% vs 0.8%,p=0.3),也未增加症状性淋巴囊肿、出血等不良事件。
要点
- 药物预防未显著降低根治性前列腺切除术后30天症状性VTE发生率。
- 药物预防未增加症状性淋巴囊肿、血肿或出血等不良事件。
- 所有VTE事件均发生于接受盆腔淋巴结清扫的患者。
核心结论
- 围手术期药物预防未能显著降低根治性前列腺切除术后症状性静脉血栓栓塞的发生率。
- 药物预防未增加症状性淋巴囊肿、出血或其他不良事件。
- 鉴于事件发生率低于预设把握度,需在高危患者(Caprini评分≥8)或接受盆腔淋巴结清扫的患者中进一步研究。
- 所有静脉血栓栓塞事件(7例症状性和3例无症状性)均发生于接受盆腔淋巴结清扫的患者。
研究设计与样本
- 前瞻性、4期、单中心、随机临床试验,纳入501例接受开放或机器人辅助腹腔镜根治性前列腺切除术的前列腺癌患者。
- 干预为皮下肝素药物预防加常规护理对比单纯常规护理。
- 筛查亚队列在30天时接受下肢双功能超声检查。
- 主要疗效结局为症状性静脉血栓栓塞(肺栓塞或深静脉血栓)发生率,主要安全结局包括症状性淋巴囊肿、血肿或术后出血。
- 采用Fisher精确检验和改良Poisson回归进行统计分析。
主要发现
- 第二次中期分析(N=445)时,常规护理组症状性VTE发生率为2.3%(4例PE+DVT和1例DVT),药物预防组为0.9%(1例PE+DVT和1例DVT),相对风险0.40(95%CI 0.08-2.03),p=0.3,达到无效阈值而提前终止。
- 筛查亚队列中,总体VTE发生率常规护理组为3.3%,药物预防组为2.4%(p=0.7)。
- 最终分析结果相似:症状性VTE发生率2.0% vs 0.8%(p=0.3);总体VTE发生率2.9% vs 2.8%(p=1)。
- 安全结局或次要结局未见差异。
关键数值与推荐
- 症状性VTE相对风险0.40(95%CI 0.08-2.03),p=0.3。
- 最终分析症状性VTE发生率2.0% vs 0.8%,p=0.3;总体VTE发生率2.9% vs 2.8%,p=1。
- 筛查亚队列总体VTE发生率3.3% vs 2.4%,p=0.7。
临床怎么用
- 对于常规风险的根治性前列腺切除术患者,药物预防未显示显著降低症状性VTE,但未增加不良事件。
- 对于有危险因素的患者,药物预防可安全实施。
- 需特别关注接受盆腔淋巴结清扫的患者,所有VTE事件均发生于该人群。
局限性
- 事件发生率低于预设把握度,研究可能不足以检测出显著差异。
- 单中心设计可能限制普遍性。
- 提前终止可能影响结果的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct high-quality evidence is lacking evaluating perioperative pharmacologic prophylaxis (PP) after radical prostatectomy (RP) to prevent venous thromboembolism (VTE) leading to significant practice variation. OBJECTIVE: To study the impact of in-hospital PP on symptomatic VTE incidence and adverse events after RP at 30 d, with the secondary objective of evaluating overall VTE in a screening subcohort. DESIGN, SETTING, AND PARTICIPANTS: A prospective, phase 4, single-center, randomized trial of men with prostate cancer undergoing open or robotic-assisted laparoscopic RP was conducted (July 2017-November 2018). INTERVENTION: PP (subcutaneous heparin) plus routine care versus routine care alone. The screening subcohort was offered lower extremity duplex ultrasound at 30 d. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: The primary efficacy outcome was symptomatic VTE incidence (pulmonary embolism [PE] or deep venous thrombosis [DVT]). Primary safety outcomes included the incidence of symptomatic lymphocele, hematoma, or bleeding after surgery. Secondary outcomes were overall VTE, estimated blood loss, total surgical drain output, complications, and surveillance imaging bias. Fisher's exact test and modified Poisson regression were performed. RESULTS AND LIMITATIONS: A total of 501 patients (75% robotic) were randomized and >99% (500/501) completed follow-up. At second interim analysis (N = 445), the symptomatic VTE rate was 2.3% (four PE + DVT and one DVT) for routine care versus 0.9% (one PE + DVT and one DVT) for PP (relative risk 0.40 [95% confidence interval 0.08-2.03], p = 0.3) meeting a futility threshold for early stopping. In the screening subcohort, the overall VTE rate was 3.3% versus 2.4% (p = 0.7). Results were similar at the final analysis (symptomatic VTE: 2.0% vs 0.8%, p = 0.3; overall VTE: 2.9% vs 2.8%, p = 1). No differences were observed in safety or secondary outcomes. All VTE events (seven symptomatic and three asymptomatic) occurred in patients undergoing pelvic lymph node dissection. CONCLUSIONS: This study was not able to demonstrate a statistically significant reduction in symptomatic VTE associated with PP. There was no increase in the development of symptomatic lymphoceles, bleeding, or other adverse events. Given that the event rate was lower than powered for, further research is needed among high-risk patients (Caprini score ≥8) or patients receiving pelvic lymph node dissection. PATIENT SUMMARY: In this report, we randomized patients undergoing radical prostatectomy to perioperative pharmacologic prophylaxis or routine care alone. We found that pharmacologic prophylaxis did not reduce postoperative symptomatic venous thromboembolism significantly for men at routine risk. Importantly, pharmacologic prophylaxis did not increase adverse events, such as formation of lymphoceles or bleeding, and can safely be implemented when indicated for patients with risk factors undergoing radical prostatectomy.
引用
- Patel HD, Faisal FA, Trock BJ, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol. 2020. PMID: 32444264. doi:10.1016/j.eururo.2020.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。